Bioglutide

Bioglutide (developmental name NA-931) is a proprietary oral quad-agonist peptide developed by Biomed Industries targeting four receptors simultaneously: insulin-like growth factor-1 (IGF-1R), glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This simultaneous engagement of four metabolically relevant pathways positions it as a mechanistically novel advance beyond existing dual and triple agonists such as tirzepatide and retatrutide.

Bioglutide is notable for its oral bioavailability — a key differentiator in the injectable-dominated GLP-1 landscape — and for Phase 2 data suggesting preservation of lean muscle mass, which is a significant limitation of current GLP-1 therapies. Full peer-reviewed publication of Phase 2 results is pending as of early 2026; available data comes from conference presentations at the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) 2025 meetings.

The molecular formula and precise sequence are proprietary and have not been publicly disclosed by Biomed Industries.

The quad-agonist mechanism of Bioglutide engages four complementary pathways:

**GLP-1R activation** suppresses appetite centrally, slows gastric emptying, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. This is the shared mechanism of all approved GLP-1 receptor agonists.

**GIPR activation** enhances post-meal insulin secretion in a glucose-dependent manner, improves adipose tissue function, and contributes to appetite suppression. The combination of GLP-1R and GIPR engagement is the basis of tirzepatide.

**GCGR activation** increases hepatic glucose output (which is counterbalanced by the insulin secretagogue effects), stimulates thermogenesis and energy expenditure through brown adipose tissue activation, promotes hepatic fat oxidation, and induces secretion of FGF21.

**IGF-1R activation** is the defining differentiator. IGF-1 receptor signaling promotes protein anabolic activity and muscle protein synthesis. By co-engaging IGF-1R, Bioglutide is theorized to counteract the muscle wasting that accompanies rapid caloric restriction from GLP-1-driven appetite suppression. Phase 2 data supports this hypothesis, with no measurable loss of lean body mass reported.